



(51) International Patent Classification:

A61K 31/15 (2006.01) A61P 27/16 (2006.01)

A61K 9/48 (2006.01) A61P 35/00 (2006.01)

A61K 31/185 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2021/019457

(22) International Filing Date:

24 February 2021 (24.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/980,645 24 February 2020 (24.02.2020) US

(71) Applicant: OBLATO, INC. [US/US]; 116 Village Boulevard, Suite 200, Princeton, NJ 08540 (US).

(72) Inventors: KIM, Hyounjeong; 901-603, 26, 118beongil, Heungdeok 2-ro, Giheung-gu, Yongin-si, Gyeonggi-do 16951 (KR). KANG, Sin, Wook; 106-501 (Kumkang APT), 177, Seohyeon-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13568 (KR). KIM, Kyeongsoon; A-1805,

123, Centum dong-ro, Haeundae-gu, Busan 48050 (KR). SUNG, Ji, Hye; 1-1306, 464, Dorim-ro, Yeongdeungpo-gu, Seoul 07296 (KR).

(74) Agent: LEE, Sandra, S. et al.; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING CANCER AND TUMOR




Figure 1

(57) Abstract: Methods of treating a cancer or a tumor in a subject using a composition are provided. The composition includes a therapeutically effective amount of 2,4-disulfonyl a-phenyl tert-butyl nitron (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount decreases a growth of the cancer or the tumor.

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

COMPOSITIONS AND METHODS FOR TREATING CANCER AND TUMOR

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No.
5 62/980,645, which was filed on February 24, 2020, the entire contents of which are
incorporated by reference herein.

FIELD OF THE INVENTION

The presently disclosed subject matter relates to techniques for inhibiting the
10 development of cancers and tumors. Specifically, the presently disclosed subject matter
relates to methods and compositions for inhibiting the development of cancers and tumors.

BACKGROUND

Cancer is a group of diseases involving abnormal growth of cells that can have the
15 potential to invade other parts/tissues of a subject, causing severe malfunctions. For
example, lung cancer is a type of cancer that starts abnormal cell growth in the lungs.
There are two main types of lung cancer that can be treated differently. The first type is
non-small cell lung cancer (NSCLC). NSCLC grows slowly and causes relatively fewer
symptoms until it has advanced. Subtypes of NSCLC can include adenocarcinoma,
20 squamous cell carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, and large
cell carcinoma. The second type is small cell lung cancer (SCLC). SCLC can grow and
spread to other tissues than faster NSCLC. Due to its fast growth rates, chemotherapy
and radiation can be applied to treat SCLS. Although NSCLC can be less aggressive,
NCLC can be diagnosed at later stages, as NSCLC cases fewer symptoms until it has
25 advanced, leading to a fatal prognosis.

Cancer cells can grow uncontrollably and form a mass called a tumor. Cancer is
one of the leading causes of death and is responsible for about 1 in 6 deaths globally.
Cancer and/or tumor formation can be the result of the interaction between genetic factors
of a subject and external factors (e.g., physical carcinogens, chemical carcinogens, and
30 biological carcinogens). Despite advances in the understanding of molecular mechanisms
of cancer, there are certain side effects in currently available anti-cancer and/or anti-tumor
therapies. Although 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) can suppress
glioblastoma (GBM) tumor growth in rodent glioma model and increase the sensitivity of

other anti-cancer drugs for the GBM treatment, its therapeutic effects on the treatment of other tumors and/or cancers have not been identified.

Therefore, there is a need for improved techniques for treating cancer or tumor (e.g., NSCLC) using 2,4-ds-PBN.

5

SUMMARY

The present disclosure provides pharmaceutical compositions and methods for treating a cancer or a tumor. The method for treating a cancer or a tumor in a subject can include administering a composition that comprises a therapeutically effective amount of
10 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount can decrease a growth of the cancer or the tumor.

In certain embodiments, the cancer can be a non-small cell lung carcinoma.

In certain embodiments, the therapeutically effective amount of the 2,4-ds-PBN or
15 pharmaceutically acceptable salts thereof can be from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day.

In certain embodiments, the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be delivered to the subject via an intravenous injection or an intra-arterial injection. In non-limiting embodiments, the therapeutically
20 effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be delivered to the subject via an enteral administration or an oral administration.

In certain embodiments, the method can further include measuring an area, a volume, or a combination thereof of the cancer or the tumor. In non-limiting embodiments, the cancer volume or the tumor volume decreases by at least about 50% after
25 administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof. In non-limiting embodiments, a growth of the cancer or the tumor decreases by at least about 40% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof.

In certain embodiments, the method can further include counting apoptotic cancer
30 cells or apoptotic tumor cells. In non-limiting embodiments, a number of the apoptotic cancer cells or the apoptotic tumor cells increases by at least about 15% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof.

In certain embodiments, the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be administered to the subject at least once a week.

In certain embodiments, the method can further include administering a therapeutically effective amount of an anti-cancer agent or an anti-tumor agent to the subject. In non-limiting embodiments, the anti-cancer/tumor agent can be selected from the group consisting of a chemotherapeutic agent, a radiotherapeutic agent, a cytokine, an anti-angiogenic agent, a tyrosine kinase inhibitor (TKI), an apoptosis-inducing agent, an anti-cancer antibody, an immunotherapeutic agent, and combinations thereof.

In certain embodiments, the method can further include administering an additional therapy. The additional therapy can be selected from the group consisting of an anti-tumor therapy, an anti-cancer therapy, a chemotherapy, a targeted therapy, an immunotherapy, a radiation therapy, a radiofrequency ablation therapy, surgery, a therapy using a tumor treating fields (TTFields) device, or combinations thereof.

In certain embodiments, the present disclosure provides a pharmaceutical composition for treating a cancer or a tumor in a subject that includes a therapeutically effective amount of 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount can be present in an amount to decrease a growth of the cancer or the tumor.

In certain embodiments, the pharmaceutical composition can be in a form of a tablet, a pill, a capsule, a gel, a liquid, a syrup, a slurry, or a suspension for an oral administration or an enteral administration. In non-limiting embodiments, the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof for the oral administration or the enteral administration can be from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day.

In certain embodiments, the pharmaceutical composition can be in a form of a solution or a liquid for an intravenous injection or an intra-arterial injection. In non-limiting embodiments, the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof for the intravenous injection or the intra-arterial injection can be from about 10 mg/kg body weight/day to about 500 mg/kg body weight/day.

In certain embodiments, the cancer can be a non-small cell lung carcinoma.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a graph showing tumor volumes after administering negative control, OKN-007 (150 mg/kg, 300 mg/kg, or 600 mg/kg), or cisplatin (2 mg/kg). Each point represents the mean values $\pm$ standard deviation (S.D.) of ten independent experiments. ## represents the p-value is less than 0.01 ($p < 0.01$) compared with the negative control group by Steel's t-test. ** represents the p-value is less than 0.01 ($p < 0.01$) compared with the negative control group by Dunnett's t-test.

Figure 2 provides a graph showing tumor weights after administering negative control, OKN-007 (150 mg/kg, 300 mg/kg, or 600 mg/kg), or cisplatin (2 mg/kg). Each point represents the mean values $\pm$ standard deviation (S.D.) of ten independent experiments. ** represents the p-value is less than 0.01 ($p < 0.01$) compared with the negative control group by Dunnett's t-test.

Figure 3 provides photographs of A549 tumor-bearing nude mice at the end of the observation period after administering negative control, OKN-007 (150 mg/kg, 300 mg/kg, or 600 mg/kg), or cisplatin (2 mg/kg).

Figure 4 provides photographs of tumors removed from A549 tumor-bearing nude mice at the end of the observation period after administering negative control or OKN-007 (150 mg/kg). In the negative control group (G1), the tumor size and volume increase over time. The OKN-007 (150 mg/kg) treated group (G2) shows a statistically significant decrease in tumor volume and size compared to the negative control group (G1).

Figure 5 provides photographs of tumors removed from A549 tumor-bearing nude mice at the end of the observation period after administering negative OKN-007 (300 or 600 mg/kg). The OKN-007 (300 mg/kg) treated group (G3) and the OKN-007 (600 mg/kg) treated group (G4) show a statistically significant decrease in tumor volume and size compared to the negative control group (G1).

Figure 6 provides photographs of tumors removed from A549 tumor-bearing nude mice at the end of the observation period after administering cisplatin (2 mg/kg). As a positive control, the cisplatin (2 mg/kg) treated group (G5) shows a statistically significant decrease in tumor volume and size compared to the negative control.

Figure 7 provides hematoxylin and eosin (H&E) staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay images of tumors harvested from the negative control-treated group (G1). Necrosis of the tumors was evaluated by the H&E staining images, and apoptosis of tumor cells was evaluated by the TUNEL assay images.

Figure 8 provides H&E staining and TUNEL assay images of tumors harvested from the OKN-007 (150 mg/kg) treated group (G2). The OKN-007 (150 mg/kg) treated group (G2) shows a significant increase in the number of apoptotic cells (arrow) in the tumor compared to the negative control group (G1).

5 **Figure 9** provides H&E staining and TUNEL assay images of tumors harvested from the OKN-007 (300 mg/kg) treated group (G3). The OKN-007 (300 mg/kg) treated group (G3) shows a significant increase in the number of apoptotic cells (arrow) in the tumor compared to the negative control group (G1).

10 **Figure 10** provides H&E staining and TUNEL assay images of tumors harvested from the OKN-007 (600 mg/kg) treated group (G4). The OKN-007 (600 mg/kg) treated group (G4) shows a significant increase in the number of apoptotic cells (arrow) in the tumor compared to the negative control group (G1).

15 **Figure 11** provides H&E staining and TUNEL assay images of tumors harvested from the cisplatin (2 mg/kg) treated group (G5). As a positive control, the cisplatin (2 mg/kg) treated group (G5) shows a significant increase in the number of apoptotic cells (arrow) in the tumor compared to the negative control group (G1).

DETAILED DESCRIPTION

20 The detailed description of the disclosed subject matter is divided into the following subsections for clarity and not by way of limitation:

- I. Definitions;
- II. Pharmaceutical Compositions; and
- III. Methods of Use.

25 **I. DEFINITIONS**

30 The terms used in this specification generally have their ordinary meanings in the art, within the context of the disclosed subject matter and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions and methods of the disclosed subject matter.

As used herein, the use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Still further, the terms “having,” “including,” “containing,” and “comprising” are

interchangeable, and one of skill in the art is cognizant that these terms are open-ended terms.

The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, *i.e.*, the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value.

As used herein, the term “administering” can mean any suitable route (e.g., systemic administration, oral administration, and intravenous administration).

The term “agent,” as used herein, means a substance that produces or is capable of producing an effect and would include, but is not limited to, chemicals, pharmaceuticals, biologics, small organic molecules, antibodies, nucleic acids, peptides, and proteins.

An “anti-cancer effect” or an “anti-tumor effect” refers to one or more of a reduction in aggregate cancer cell mass, a reduction in cancer cell growth rate, a reduction in cancer progression, a reduction in cancer cell proliferation, a reduction in tumor mass, a reduction in tumor volume, a reduction in tumor cell proliferation, a reduction in tumor growth rate and/or a reduction in tumor metastasis. In certain embodiments, an anti-cancer effect can refer to a complete response, a partial response, a stable disease (without progression or relapse), a response with a later relapse, or progression-free survival in a patient diagnosed with cancer.

An “anti-cancer agent” or an “anti-tumor agent” as used herein, can be any molecule, compound, chemical, or composition that has an anti-cancer effect. Anti-cancer agents include, but are not limited to, chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, tyrosine kinase inhibitors (TKI), apoptosis-inducing agents, anti-cancer antibodies, and/or agents that promote the activity of the immune system. In certain embodiments, an anti-cancer agent can be a radiotherapeutic agent. In certain embodiments, an anti-cancer agent can be an immunotherapeutic agent. In certain embodiments, an anti-cancer agent can be a chemotherapeutic agent. Other non-limiting exemplary anti-cancer agents that can be used with the presently disclosed subject matter include tumor-antigen based vaccines and chimeric antigen receptor T-cells.

As used herein, the term “co-administer” is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of additional therapies. The composition of the disclosure can be administered alone or can be co-administered with a second composition/therapeutic agent to a subject. Co-administration is meant to include simultaneous or sequential administration of the composition individually or in combination with a second composition/therapeutic agent. Additionally, the first and second agents can be formulated separately or together in one or more compositions.

As used herein, “comprises,” “comprising,” “containing” and “having” and the like can have the meaning ascribed to them in U.S. Patent law and can mean “includes,” “including,” and the like; “consisting essentially of” or “consists essentially” likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

As used herein, “concurrent administration” includes overlapping in duration at least in part. For example, when two agents (*e.g.*, any of the compositions described herein) are administered concurrently, their administration occurs within a certain desired time. The compositions’ administration can begin and end on the same day. The administration of one composition can also precede the administration of a second composition by day(s) as long as both compositions are taken on the same day at least once. Similarly, the administration of one composition can extend beyond the administration of a second composition as long as both compositions are taken on the same day at least once. The compositions do not have to be taken at the same time each day to include concurrent administration.

As used herein, the term “disease” refers to any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.

The terms “detection” or “detecting” include any means of detecting, including direct and indirect detection.

The term “dosage” is intended to encompass a formulation expressed in terms of total amounts for a given timeframe, for example, as $\mu\text{g/kg/hr}$, $\mu\text{g/kg/day}$, mg/kg/day , or mg/kg/hr . The dosage is the amount of an ingredient administered in accordance with a particular dosage regimen. A “dose” is an amount of an agent administered to a mammal in a unit volume or mass, *e.g.*, an absolute unit dose expressed in mg of the agent. The

dose depends on the concentration of the agent in the formulation, *e.g.*, in moles per liter (M), mass per volume (m/v), or mass per mass (m/m). The two terms are closely related, as a particular dosage results from the regimen of administration of a dose or doses of the formulation. The particular meaning, in any case, will be apparent from the context.

5 An “effective amount” or “therapeutically effective amount” of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result, *e.g.*, treating cancer in a subject. A therapeutically effective amount can be administered in one or more administrations.

10 An “individual” or “subject” herein is a vertebrate, such as a human or non-human animal, for example, a mammal. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents, and pets. Non-limiting examples of non-human animal subjects include rodents such as mice, rats, hamsters, and guinea pigs; rabbits; dogs; cats; sheep; pigs; goats; cattle; horses; and non-human primates such as apes and monkeys.

15 The terms “inhibiting,” “eliminating,” “decreasing,” “reducing,” or “preventing,” or any variation of these terms, referred to herein, include any measurable decrease or complete inhibition to achieve a desired result.

 The term “in need thereof” would be a subject known or suspected of having or being at risk of developing a disease, *e.g.*, cancer.

20 As used herein, “liquid” is a dosage form consisting of a composition in its liquid state. A liquid is pourable; it flows and conforms to its container at room temperature. Liquids display Newtonian or pseudoplastic flow behavior. In certain embodiments, a “semi-liquid” as used herein can have properties of both a liquid and another formulation (*i.e.*, a suspension, an emulsion, a solution, a cream, a gel, a jelly, and the like).

25 As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The type of carrier can be selected based upon the intended route of administration. The use of such media and agents for pharmaceutically active substances is well known in the art.

30 As used herein, the terms “prevent,” “preventing,” or “prevention,” “prophylactic treatment,” and the like refer to reducing the probability of developing a disorder or condition in a subject who does not have but is at risk of or susceptible to developing a disorder or condition. The prevention can be complete (*i.e.*, no detectable symptoms) or partial so that fewer symptoms are observed than would likely occur absent treatment. The

terms further include a prophylactic benefit. For disease or condition to be prevented, the compositions can be administered to a patient at risk of developing a particular disease or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease cannot have been made.

5 As used herein, a “solution” is a clear, homogeneous liquid dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents. A solution is a liquid preparation that contains one or more dissolved chemical substances in a suitable solvent or mixture of mutually miscible solvents. Because molecules of a drug substance in solution are uniformly dispersed, the use of
10 solutions as dosage forms generally provides assurance of uniform dosage upon administration and good accuracy when the solution is diluted or otherwise mixed.

 As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated and can be performed either for prophylaxis or during the course
15 of clinical pathology. Desirable effects of treatment include, but are not limited to, prolonging survival, preventing recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In certain embodiments,
20 antibodies of the presently disclosed subject matter are used to delay the development of a disease or to slow the progression of a disease, *e.g.*, cancer and/or tumor.


 As used herein, “sequential administration” includes that the administration of two agents (*e.g.*, compositions described herein) occurs separately on the same day or does not occur on the same day (*e.g.*, occurs on consecutive days).

25 As described herein, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.

30 II. PHARMACEUTICAL COMPOSITIONS

 The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) or pharmaceutically acceptable salts thereof to decrease a growth of the cancer or the tumor.

In certain embodiments, 2,4-ds-PBN can exist in the following acid form of Formula I as a solid or in solution in lower pH conditions:




2,4-disulfonyl PBN

Formula I

- 5 In non-limiting embodiments, 2,4-ds-PBN can exist in the following ionized salt form of Formula II or Formula III at higher pH conditions:

Formula II



Formula III

10

- In some embodiments, X in Formula III can be a pharmaceutically acceptable cation. For example, this cation can be a monovalent material such as sodium, potassium, or ammonium. In non-limiting embodiments, the cation can be a multivalent alone or cation in combination with a pharmaceutically acceptable monovalent anion. For example, the pharmaceutically acceptable monovalent anion can include calcium with chloride, bromide, iodide, hydroxyl, nitrate, sulfonate, acetate, tartrate, oxalate, succinate, palmoate or the like anion, magnesium with such anions, zinc with such anions, or the like. In non-limiting embodiments, the free acid and the sodium, potassium, calcium, magnesium, or ammonium salts can be preferred.

20

In certain embodiments, the 2,4-ds-PBN can be prepared by a two-step reaction sequence. For example, tertiary butyl nitrate (2-methyl-2-nitropropane) can be converted

to the corresponding n-hydroxylamine using a suitable catalyst such as an activated zinc/acetic acid catalyst or an aluminum/mercury amalgam catalyst. This reaction can be carried out in about 0.5 to 12 hours and especially about 2 to 6 hours or so at a temperature of about 15-100° C in a liquid reaction medium such as alcohol/water mixture in the case of the zinc catalyst or an ether/water mixture in the case of the aluminum amalgam catalyst. The freshly formed hydroxylamine can be reacted with 4-formyl-1,3-benzenedisulfonic acid, with a slight excess of the amine being used. This reaction can be carried out at similar temperature conditions. This reaction can be completed in from about 10 to about 24 hours. The formed material through the two reactions can be the free acid and be characterized by a molecular weight of 337.3 g/mole. In some embodiments, the formed material can be a white powdery material that decomposes upon heating. In non-limiting embodiments, the formed material can be characterized by solubility in water of greater than 1 gram/ml and a ¹H NMR spectrum in D₂O of 8.048 ppm (dd, 8.4, 1.7 Hz); 8.836 ppm (d, 8.4 Hz); 8.839 ppm (d, 1.7 Hz); 8.774 ppm (s).

The various salts can be easily formed by admixing the free acid in a medium with a base, for example, KOH for potassium salt, and the like.

In certain embodiments, the disclosed composition can have improved transport efficiency. For example, the 2,4-ds-PBN can provide improved transport efficiency across the blood/brain barrier.

In certain embodiments, the pharmaceutical compositions suitable for use in the presently disclosed subject matter can include compositions where the active ingredients, e.g., 2,4-ds-PBN, are contained in a therapeutically effective amount. The therapeutically effective amount of an active ingredient can vary depending on the active ingredient, compositions used, cancer and/or tumor and its severity, and the age, weight, etc., of the subject to be treated. In certain embodiments, a subject can receive a therapeutically effective amount of the disclosed composition in single or multiple administrations of one or more composition, which can depend on the dosage and frequency as required and tolerated by the patient.

In certain embodiments, the therapeutically effective amount of 2,4-ds-PBN or pharmaceutically acceptable salts thereof in the pharmaceutical composition can be at least about 5 mg/kg body weight/day, at least about 10 mg/kg body weight/day, at least about 20 mg/kg body weight/day, at least about 50 mg/kg body weight/day, at least about 100 mg/kg body weight/day, at least about 200 mg/kg body weight/day, at least about 300 mg/kg body weight/day, at least about 400 mg/kg body weight/day, at least about 500

mg/kg body weight/day, at least about 600 mg/kg body weight/day, at least about 700 mg/kg body weight/day, at least about 800 mg/kg body weight/day, at least about 900 mg/kg body weight/day, or at least about 1,000 mg/kg body weight/day. In non-limiting embodiments, the effective dose can be from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 300 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 200 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 100 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 600 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 200 mg/kg body weight/day, from about 60 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 70 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 80 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 90 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 100 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 200 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 300 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 400 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 500 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 600 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 700 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 800 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 900 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 800 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 700 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 600 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 300 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 200 mg/kg body weight/day, or from about 5 mg/kg body weight/day to about 100 mg/kg body weight/day.

The pharmaceutical composition containing the active compound (e.g., 2,4-ds-PBN) can contain a physiologically compatible vehicle, as those skilled in the art can select using conventional criteria. Suitable pharmaceutically acceptable vehicles that can be used with the presently disclosed subject matter have the characteristics of not interfering with the effectiveness of the biological activity of the active ingredients, *e.g.*, 2,4-ds-PBN, and that is not toxic to the patient to whom it is administered. In non-limiting embodiments, suitable pharmaceutical vehicles can include phosphate-buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, and sterile solutions. Additional non-limiting examples of pharmaceutically acceptable vehicles include gels, bioabsorbable matrix materials, implantation elements containing the inhibitor and/or any other suitable vehicle, delivery, or dispensing means or material. Such pharmaceutically acceptable vehicles can be formulated by conventional methods and can be administered to the subject. In certain embodiments, the pharmaceutical acceptable vehicles can include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as, but not limited to, octadecyl dimethyl benzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, butyl or benzyl alcohol, alkyl parabens such as methyl or propylparaben, catechol, resorcinol, cyclohexanol, 3-pentanol and *m*-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (*e.g.*, Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). In certain embodiments, the suitable pharmaceutically acceptable vehicles can include one or more of water, saline, phosphate-buffered saline, dextrose, glycerol, ethanol, or combinations thereof.

In certain embodiments, the pharmaceutical composition can be formulated for oral administration. For example, the pharmaceutical compositions of the present disclosure can be formulated using pharmaceutically acceptable carriers well known in the art that are suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral or nasal ingestion by a patient to be treated. In non-limiting embodiments,

the pharmaceutical composition can be a solid dosage form. In some embodiments, the tablet can be an immediate-release tablet. Alternatively or additionally, the tablet can be an extended or controlled release tablet. The solid dosage can include both an immediate release portion and an extended or controlled release portion.

5 In certain embodiments, the pharmaceutical composition can be formulated as an enteric-coated tablet or an enteric-coated capsule. For example, 2,4-ds-PBN can be enterically coated with at least one coating layer. In non-limiting embodiments, a coating material for enteric coating can include a delayed-release enteric polymers. Suitable examples of delayed-release enteric polymers can include, but are not limited to cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters such as, for instance, materials known under the trade name EUDRAGIT® L12.5, L100, EUDRAGIT® S12.5, S100, or similar compounds used to obtain enteric coatings. Co-polymerized methacrylic acid/methacrylic acid methyl esters can include three subclasses of compound: methacrylic acid copolymer type A, methacrylic acid copolymer type B, and methacrylic acid copolymer type C. The various types of copolymers represent compounds with varying ratios of methacrylic acid to methacrylic acid methyl ester. For example, methacrylic acid copolymer type A has a ratio of methacrylic acid to methacrylic acid methyl ester of approximately 1:1, type B has a ratio of approximately 1:2, and type C has a ratio similar to type A, but can incorporate additional components, such as surfactants. Aqueous colloidal polymer dispersions or re-dispersions can also be applied, including, for example, the polymers sold under the trade name EUDRAGIT® L 30D-55, EUDRAGIT® L100-55, EUDRAGIT® S100, EUDRAGIT® preparation 4110D (Rohm Pharma); EUDAGRITO FS 30D; 25 AQUATERIC®, AQUACOAT® CPD 30 (FMC); KOLLICOAT MAE® 30D and 30DP (BASF); and EASTACRYL® 30D (Eastman Chemical). In some embodiments, the delayed-release enteric polymer can include methacrylic acid copolymer type A. In non-limiting embodiments, the delayed-release enteric polymer can include a mixture of methacrylic acid copolymer type A and methacrylic acid copolymer type B. One skilled in the art will appreciate that additional components can be added to the delayed-release polymers without departing from the scope of the disclosure. For example, a plasticizer can be added to the delayed-release enteric polymers to improve the physical characteristics of the delayed-release polymeric layer. Non-limiting examples of plasticizers can include triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl

citrate, trihexyl citrate, acetyl trihexyl citrate, trioctyl citrate, acetyl trioctyl citrate, butyryl trihexyl citrate, acetyl butyryl trihexyl citrate, trimethyl citrate, acetylated monoglycerides, alkyl sulphonic acid phenyl esters, or combinations thereof. In some embodiments, the plasticizer can include triethyl citrate.

5 In certain embodiments, the disclosed enteric polymers can be modified by mixing with other known coating products that are not pH sensitive. Examples of such coating products can include the neutral methacrylic acid esters with a small portion of trimethylammonioethyl methacrylate chloride, sold currently under the trade names EUDRAGIT® and EUDRAGIT® RL; a neutral ester dispersion without any functional
10 groups, sold under the trade names EUDRAGIT® NE30D and EUDRAGIT® NE30; and other pH-independent coating products.

In certain embodiments, an additional modifying layer can be added on top of the enteric coating layer. This modifying layer can include a water penetration barrier layer (semipermeable polymer), which can be successively coated after the enteric coating to
15 reduce the water penetration rate through the enteric coating layer and thus increase the lag time of the drug release. Controlled-release coatings known to one skilled in the art can be used for this purpose by coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions. For example, the following non-limiting list of controlled release
20 polymers can be used in the current disclosure: cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethylcellulose, hydroxypropyl methylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate),
25 poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), poly(ethylene), poly(ethylene) low density, poly(ethylene) high density, poly(propylene), poly(ethylene oxide), poly(ethylene terephthalate), poly(vinyl isobutyl ether), poly(vinyl acetate),
30 poly(vinyl chloride), polyurethane, ethylcellulose aqueous dispersions such as AQUACOAT® and SURELEASE®, poly(butyl methacrylate, (2-dimethylaminoethyl) methacrylate, methyl methacrylate), poly(methacrylic acid, methyl methacrylate), poly(methacrylic acid, ethylacrylate), poly(methyl acrylate, methyl methacrylate, methacrylic acid), poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl

methacrylate chloride), poly(ethylacrylate, methyl methacrylate), poly(methacrylic acid, ethylacrylate), type A methacrylic acid copolymer, type B methacrylic acid copolymer, type C methacrylic acid copolymer, methacrylic acid copolymer dispersion, aqueous acrylic polymer dispersion, (EUDRAGIT® compounds), OPADRY®, fatty acids and their esters, waxes, zein, and aqueous polymer dispersions such as EUDRAGIT® RS and RL 30D, EUDRAGIT® NE 30D, cellulose acetate latex. The combination of the above polymers and hydrophilic polymers such as hydroxyethyl cellulose, hydroxypropyl cellulose (KLUCEL®, Hercules Corp.), hydroxypropyl methylcellulose (METHOCEL®, Dow Chemical Corp.), and polyvinylpyrrolidone can be incorporated. In non-limiting 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10100 10105 10110 10115 10120 10125 10130 10135 10140 10145 10150 10155 10160 10165 10170 10175 10180 10185 10190 10195 10200 10205 10210 10215 10220 10225 10230 10235 10240 10245 10250 10255 10260 10265 10270 10275 10280 10285 10290 10295 10300 10305 10310 10315 10320 10325 10330 10335 10340 10345 10350 10355 10360 10365 10370 10375 10380 10385 10390 10395 10400 10405 10410 10415 10420 10425 10430 10435 10440 10445 10450 10455 10460 10465 10470 10475 10480 10485 10490 10495 10500 10505 10510 10515 10520 10525 10530 10535 10540 10545 10550 10555 10560 10565 10570 10575 10580 10585 10590 10595 10600 10605 10610 10615 10620 10625 10630 10635 10640 10645 10650 10655 10660 10665 10670 10675 10680 10685 10690 10695 10700 10705 10710 10715 10720 10725 10730 10735 10740 10745 10750 10755 10760 10765 10770 10775 10780 10785 10790 10795 10800 10805 10810 10815 10820 10825 10830 10835 10840 10845 10850 10855 10860 10865 10870 10875 10880 10885 10890 10895 10900 10905 10910 10915 10920 10925 10930 10935 10940 10945 10950 10955 10960 10965 10970 10975 10980 10985 10990 10995 11000 11005 11010 11015 11020 11025 11030 11035 11040 11045 11050 11055 11060 11065 11070 11075 11080 11085 11090 11095 11100 11105 11110 11115 11120 11125 11130 11135 11140 11145 11150 11155 11160 11165 11170 11175 11180 11185 11190 11195 11200 11205 11210 11215 11220 11225 11230 11235 11240 11245 11250 11255 11260 11265 11270 11275 11280 11285 11290 11295 11300 11305 11310 11315 11320 11325 11330 11335 11340 11345 11350 11355 11360 11365 11370 11375 11380 11385 11390 11395 11400 11405 11410 11415 11420 11425 11430 11435 11440 11445 11450 11455 11460 11465 11470 11475 11480 11485 11490 11495 11500 11505 11510 11515 11520 11525 11530 11535 11540 11545 11550 11555 11560 11565 11570 11575 11580 11585 11590 11595 11600 11605 11610 11615 11620 11625 11630 11635 11640 11645 11650 11655 11660 11665 11670 11675 11680 11685 11690 11695 11700 11705 11710 11715 11720 11725 11730 11735 11740 11745 11750 11755 11760 11765 11770 11775 11780 11785 11790 11795 11800 11805 11810 11815 11820 11825 11830 11835 11840 11845 11850 11855 11860 11865 11870 11875 11880 11885 11890 11895 1

and “administered parenterally,” as used herein, refers to modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion. For example, and not by way of limitation, pharmaceutical compositions of the present disclosure can be administered to the patient intravenously in a pharmaceutically acceptable carrier such as physiological saline. In certain embodiments, the present disclosure provides a parenteral pharmaceutical composition comprising inhibitors disclosed herein.

In non-limiting embodiments, the disclosed composition can include a therapeutically effective amount of 2,4-ds-PBN or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount can be present in an amount to decrease a growth of the cancer or the tumor, and wherein the cancer can be a non-small cell lung carcinoma, wherein the pharmaceutical composition can be in a form of a tablet, a pill, a capsule, a gel, a liquid, a syrup, a slurry, or a suspension for oral administration or an enteral administration, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof for oral administration or the enteral administration can be from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day, wherein the composition can include at least one coating layer that can encapsulate the 2,4-ds-PBN or pharmaceutically acceptable salts thereof and solubilize at a predetermined range of pH, or alternatively wherein the pharmaceutical composition can be in a form of a solution or a liquid for an intravenous injection or an intra-arterial injection, and wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof for the intravenous injection or the intra-arterial injection can be from about 10 mg/kg body weight/day to about 500 mg/kg body weight/day.

III. METHODS

The present disclosure provides a method of treating a cancer or a tumor in a subject. The method includes administering a composition that comprises a therapeutically effective amount of 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) to decrease a growth of the cancer or the tumor.

In certain embodiments, administering the effective dose of the composition can treat or prevent the occurrence, recurrence, spread, growth, metastasis, or vascularization of the target tumor or the target cancer. In non-limiting embodiments, the growth of the tumor or cancer can be reduced by at least about 1%, at least about 3%, at least about 5%,
5 at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65% or at least about 70%.

In non-limiting embodiments, administering the effective dose of the composition can decrease the target tumor and/or cancer's area, a volume, or a combination thereof. In
10 non-limiting embodiments, the tumor and/or cancer volume can be reduced by at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, or at least about 70%. For example, the non-small cell lung carcinoma's
15 volume can decrease by about 70% after delivering the pharmaceutical composition to the target cancer and/or the target tumor.

In certain embodiments, the method can further include assessing the efficacy of the composition by measuring the volume of cancer or the tumor. For example, the largest diameter (a) and the smallest diameter (b) of each tumor can be measured for estimation
20 of the tumor and/or cancer area or volume at least 1, 2, 3, 4, 8, 12, 18, or 24 times a week, or more.

In certain embodiments, administering the effective dose of the composition can increase apoptosis or necrosis of target tumor and/or cancer cells. For example, a grade of the target tumor and/or cancer's apoptotic or necrosis activity can increase. The grade can
25 be determined by the number of positive cells per histogram area of the target tumor and/or the target cancer (e.g., about 1 mm²). The apoptotic or necrosis grade can be determined by calculating the average number of positive cells and graded into the corresponding severity (e.g., minimal, slight, moderate, marked, and severe). In non-limiting embodiments, a total number or a mean value of the predetermined area of the target cancer
30 and/or the target tumor can decrease after administering the disclosed composition. For example, the mean value of counting of apoptotic cells can increase by at least about 15%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, or at least about 130%. In some embodiments,

administering the effective dose of the composition can increase apoptosis of target tumor and/or cancer cells can increase the mean value of counting of apoptotic cells by about 130%.

5 In certain embodiments, the method can further include assessing the efficacy of the composition by counting apoptotic cancer cells or apoptosis tumor cells. For example, the target tumor or cancer can be obtained from a patient and be prepared for hematoxylin & eosin (H&E) staining and TUNEL staining. Necrosis of the obtained cancers/tumors can be evaluated by H&E staining, and apoptosis of the obtained cancers/tumors can be evaluated by the number of TUNEL staining positive cells per predetermined area (e.g., 1
10 mm²). In some embodiments, the apoptosis of the tumor and/or cancer can be determined by calculating the average number of positive cells and graded into the corresponding severity (e.g., minimal, slight, moderate, marked, and severe).

In certain embodiments, the target cancer can be non-small cell lung carcinoma and solid cancers (e.g., gastric cancer, colon cancer, breast cancer, and the like).

15 Dosage Regimens

For example and not limitation, the administration of the disclosed subject matter can be oral administration, systemic administration, intravenous administration, or local injection to target tissues. An example of oral administration can include delivering the composition containing 2,4-ds-PBN or pharmaceutically acceptable salts to decrease the
20 growth of cancer or the tumor in the form of tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions, and the like to a subject through the mouth of the subject. An example of systemic administration includes intravenous, intraperitoneal, intramuscular, or subcutaneous injections, inhalation (orally or nasally), transdermal, suppository, or enema administration of a composition containing 2,4-ds-PBN or pharmaceutically
25 acceptable salts to decrease the growth of cancer or the tumor. In some embodiments, the pharmaceutical composition can be in the form of a solution for systemic administration, intravenous administration, or local injection to the target cancer or tumor.

In certain embodiments, the following dosage regimens can be used to treat a cancer or a tumor in a subject. In non-limiting embodiments, the composition for oral
30 administration can include the 2,4-ds-PBN or pharmaceutically acceptable salts thereof at least about 5 mg/kg body weight/day, at least about 10 mg/kg body weight/day, at least about 20 mg/kg body weight/day, at least about 50 mg/kg body weight/day, at least about 100 mg/kg body weight/day, at least about 200 mg/kg body weight/day, at least about 300 mg/kg body weight/day, at least about 400 mg/kg body weight/day, at least about 500

mg/kg body weight/day, at least about 600 mg/kg body weight/day, at least about 700 mg/kg body weight/day, at least about 800 mg/kg body weight/day, at least about 900 mg/kg body weight/day, or at least about 1000 mg/kg body weight/day. In non-limiting embodiments, the effective dose for oral administration can be from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 300 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 200 mg/kg body weight/day, from about 10 mg/kg body weight/day to about 100 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 600 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 200 mg/kg body weight/day, from about 60 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 70 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 80 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 90 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 100 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 200 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 300 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 400 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 500 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 600 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 700 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 800 mg/kg body weight/day to about 1,000 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 900 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 800 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 700 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 600 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 300 mg/kg body weight/day, from about 5 mg/kg body weight/day to about 200 mg/kg body weight/day, or from about 5 mg/kg body weight/day to about 100 mg/kg body weight/day.

In certain embodiments, the composition can be administered to a subject by orally administering the disclosed dose of the composition to the subject, 1 to 4 times daily. For example, the composition can be applied 1, 2, 3, or 4 times a day or more. In certain embodiments, the composition can be applied by administering the disclosed dose of the composition to the subject, once daily, twice daily, three times daily, or four times daily. For example and not limitation, the composition can be applied by administering the disclosed dose of the composition to the target tissue three times daily, including, for example, in the morning, noon, and evening. In non-limiting embodiments, the disclosed composition can be administered in appropriate amounts divided into several portions for a specific period of time.

In certain embodiments, the composition for the systemic administration, intravenous administration, or local injection can include the 2,4-ds-PBN or pharmaceutically acceptable salts thereof at least about 10 mg/kg body weight/day, at least about 20 mg/kg body weight/day, at least about 30 mg/kg body weight/day, at least about 40 mg/kg body weight/day, at least about 50 mg/kg body weight/day, at least about 60 mg/kg body weight/day, at least about 70 mg/kg body weight/day, at least about 80 mg/kg body weight/day, at least about 90 mg/kg body weight/day, at least about 100 mg/kg body weight/day, at least about 200 mg/kg body weight/day, at least about 300 mg/kg body weight/day, at least about 400 mg/kg body weight/day, or at least about 500 mg/kg body weight/day. In non-limiting embodiments, the effective dose for the systemic administration, intravenous administration, or local injection can be from about 10 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 30 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 40 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 50 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 60 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 70 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 80 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 90 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 100 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 200 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 300 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 500 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 300 mg/kg body weight/day, from about

20 mg/kg body weight/day to about 200 mg/kg body weight/day, from about 20 mg/kg body weight/day to about 100 mg/kg body weight/day, from about 60 mg/kg body weight/day to about 400 mg/kg body weight/day, from about 60 mg/kg body weight/day to about 300 mg/kg body weight/day, or from about 60 mg/kg body weight/day to about 200 mg/kg body weight/day.

In certain embodiments, the composition for the systemic administration, intravenous administration, or local injection can be prepared in the liquid solutions or suspensions in an aqueous physiological buffer.

The composition for the systemic administration, intravenous administration, or local injection can be administered to the target cancer and/or the target tumor by delivering the composition prepared for systemic, intravenous, or local application to the target region 1, 2, 3, 4, 5, 6, or 7 times a week. In non-limiting embodiments, the pharmaceutical composition can be delivered once a week or two times a week, or three times a week, or four times a week, or 5 times a week.

In certain embodiments, the dosage administered can vary depending upon known factors, such as the route of administration, age, health, and weight of the recipient, nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. In non-limiting embodiments, the disclosed dosage regimes can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the composition. For example, the dosage of the composition can be increased if the lower dose does not provide sufficient activity in the treatment of the condition described herein (*e.g.*, non-small cell lung carcinoma). Alternatively, the dosage of the composition can be decreased if the disease (*e.g.*, non-small cell lung carcinoma) is reduced, no longer detectable, or eliminated.

In certain embodiments, the disclosed composition can be administered to the subject in a single dose or divided doses.

In certain embodiments, the duration of the disclosed treatment can be between about one day to about five years. In certain embodiments, the duration of the disclosed treatment can be about at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 2 years at least about 3 years, at least about 4 years, or at least

about 5 years. In certain embodiments, the composition can be administered until the cancers/tumors are no longer detectable.

Co-administration

In certain embodiments, the composition disclosed herein can be used alone or in
5 combination with one or more therapies. For example, but not by way of limitation, methods of the present disclosure can include administering the disclosed compositions and one or more anti-tumor or anti-cancer therapies. "In combination with," as used herein, means that the disclosed composition and the one or more therapies can be administered to a subject as part of a treatment regimen or plan. In certain embodiments, being used in
10 combination does not require that the composition and one or more agents for the additional therapies are physically combined prior to administration, administered by the same route or that they be administered over the same time frame. In certain embodiments, the agent for additional therapies can be administered before the disclosed composition. In certain embodiments, the agent for additional therapies can be administered after the
15 disclosed composition. In certain embodiments, the agent for additional therapies can be administered simultaneously with the disclosed composition. Non-limiting exemplary additional therapies can include, but are not limited to, the anti-tumor treatment, anti-cancer treatment, chemotherapy, targeted therapy, immunotherapy, radiation, radiofrequency ablation, surgery, therapy using a tumor treating fields (TTFields) device, or combinations thereof. In non-limiting embodiments, the agent for the additional
20 therapies can include cisplatin, cyclophosphamide, doxorubicin, vincristine, topotecan, pemetrexed, gefitinib, erlotinib, dacomitinib, osimertinib, nivolumab, pembrolizumab, atezolizumab, durvalumab, chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, tyrosine kinase inhibitors (TKI), apoptosis-inducing agents, anti-cancer antibodies, a targeted drug, and/or agents which promote the activity of the immune
25 system, including but not limited to cytokines such as but not limited to interleukin 2 (IL-2), interferon, an anti-CTLA4 antibody, an anti-PD-1 antibody and/or an anti-PD-L1 antibody, immune checkpoint inhibitors, immune cell therapy agents, therapeutic antibodies, anticancer vaccines, or combinations thereof. In certain embodiments, the anti-cancer agent can be a taxane, a platinum-based agent, an anthracycline, an anthraquinone, an alkylating agent, a HER2 targeting therapy, vinorelbine, a nucleoside analog, ixabepilone, eribulin, cytarabine, a hormonal therapy, methotrexate, capecitabine, lapatinib, 5-FU, etoposide or any combination thereof.
30

In certain embodiments, administering the disclosed compositions in combination with one or more additional therapies can induce combinatorial or synergistic effects for decreasing or preventing target tumor and/or cancer growth. For example, but not by way of limitation, synergistic decreases in the growth of area and volume from the target cancer and/or the target tumor can occur when combinations of the disclosed composition and additional-therapies are delivered to a subject. In non-limiting embodiments, the disclosed composition can suppress the target tumor and/or cancer growth and increase the sensitivity of the additional therapies for the target cancer and/or tumor treatment.

In non-limiting embodiments, the disclosed method for treating a cancer or a tumor in a subject in need thereof can include administering a therapeutically effective amount of 2,4-ds-PBN or pharmaceutically acceptable salts thereof, measuring a volume, an area, or a combination thereof of the cancer or the tumor, counting apoptotic cancer cells or apoptotic tumor cells, administering a therapeutically effective amount of an anti-cancer agent or an anti-tumor agent to the subject, and administering an additional therapy, wherein the therapeutically effective amount can decrease a growth of the cancer or the tumor, wherein the cancer can be a non-small cell lung carcinoma, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be from about 20 mg/kg body weight/day to about 1,200 mg/kg body weight/day, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be delivered to the subject via an intravenous injection or an intra-arterial injection or alternatively the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be delivered to the subject via an enteral administration or an oral administration, wherein the cancer volume or the tumor volume can decrease by at least about 50% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof, wherein a growth of the cancer or the tumor can decrease by at least about 40% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof, wherein a number of the apoptotic cancer cells or the apoptotic tumor cells can increase by at least about 15% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof can be delivered to the subject at least once a week, wherein the anti-cancer/tumor agent can be selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a cytokine, an anti-angiogenic

agent, a tyrosine kinase inhibitor (TKI), an apoptosis-inducing agent, an anti-cancer antibody, and combinations thereof, wherein the additional therapy can be selected from the group consisting of an anti-tumor therapy, an anti-cancer therapy, a chemotherapy, a targeted therapy, an immunotherapy, a radiation therapy, a radiofrequency ablation therapy, surgery, a therapy using a tumor treating fields (TTFields) device, or combinations thereof .

EXAMPLES

The presently disclosed subject matter will be better understood by reference to the following Examples, which are provided as exemplary of the presently disclosed subject matter, and not by way of limitation

EXAMPLE: Anti-Carcinogenic Effects of OKN-007 on Human Lung Cancer Cell Line A549 Xenografted in Nude Mice

The anti-cancer efficacy of OKN-007 was assessed after oral administration in nude mice carrying human A549 lung cancer xenografts implanted subcutaneously in the flank.

Materials and Methods:

Test Substance was OKN-007 that refers to 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN, Disodium 4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate) and has the molecular formula: $C_{11}H_{13}NO_7S_2 \cdot Na_2$.

The positive substance was Cis-Diammineplatinum (II) dichloride (Cisplatin), which has the molecular formula: $Pt(NH_3)_2Cl_2$.

Saline was used as a negative control.

Preparation of test substance: The required amount of the test substance was placed in a tube. A small amount of vehicles was added and mixed. The vehicle was gradually added to yield the desired concentrations (e.g., 15, 30, and 60 mg/mL).

Preparation of Positive control: The required amount of the positive control substance was placed in a tube. A small amount of saline was added and mixed. Saline was gradually added to yield the desired concentration (e.g., 0.2 mg/mL).

Human lung cancer cell line, A549 was used.

For Culture medium: Fetal bovine serum (FBS), Penicillin-Streptomycin (10,000 units/mL of penicillin and 10,000 µg/mL of streptomycin), and RPMI1640 were mixed per 100 mL as showing in Table 1.

Name	Amount (mL)
FBS (Lot No.: 1982135, Gibco, U.S.A)	10
Penicillin-Streptomycin (Lot No.: 2019315, Gibco, U.S.A.)	1
RPMI1640 (0000704247, Lonza, U.S.A.)	89
Total volume	100

5 Table 1. Culture medium.

Preparation of cell culture: The frozen cells were thawed in a water bath. Cells were placed in a tube containing the medium and centrifuged (1,000 rpm, 5 minutes) to discard the supernatant. After re-suspending with the culture medium, cells were placed in a cell culture flask and incubated in a 5% CO₂ incubator at 37°C. Cells were sub-cultured at a ratio of 1:5 when grown with confluency of 70 – 80% in the culture container. Cells cultured on the day of cell line transplantation were centrifuged (1,000 rpm, 5 minutes) to discard the supernatant and to make cell suspension with D-PBS. Then, the cell suspension was mixed with Matrigel at a ratio of 1:1 (5×10^7 cells/mL).

BALB/c Nude mouse, CAnN.Cg-Foxn1nu/CrlOri, SPF was used. Sex, number, age, and body weight range of animals at receipt: The mice (65 mice) were male, 5 weeks old, and had about 14.5 – 19.6 g weight at the receipt.

Sex, number, age, and body weight range of animals at the start of administration: The mice (50 mice) were male, 7 weeks old, and had about 18.4 – 24.0 g weight at the start of administration.

Cell transplantation: After the quarantine-acclimation period, the body weight measurement and cell transplantation in healthy animals were performed. All animals were observed for clinical signs every week. Prepared cell (1×10^7 cells/0.2 mL) suspension was injected subcutaneously into the right flank with disposable syringes. Animals were observed for clinical signs once daily during the transplantation and engraftment period.

Group assignment: After transplanting cells, each tumor size was monitored for 65 animals. When tumor volume reached within 87 – 112 mm³, 50 animals were assigned to the respective groups with an average tumor volume of about 99 mm³. Based on the tumor volume, animals were selected and randomly distributed into 5 groups (10 animals/group).

Dosing Route: Oral administration. The route of administration was oral because the clinical application of the test substance is oral.

Method and frequency of administration: For negative control and test substance, oral administration was performed once a day for 4 weeks for a total of 28 times using a disposable syringe. For positive control, intraperitoneal administration was performed once a week for 4 weeks for a total of 4 times using a disposable syringe.

Group	Route	Dose (mg/kg)	Dose volume (mL/kg)	Number of animals (Animal No.)
G1 Negative control	P.O.	0	10	10 (1101–1110)
G2 Test substance 1	P.O.	150	10	10 (1201–1210)
G3 Test substance 2	P.O.	300	10	10 (1301–1310)
G4 Test substance 3	P.O.	600	10	10 (1401–1410)
G5 Positive control	I.P.	2	10	10 (1501–1510)

Table II. Group designation.

Dosing Route: The dose levels of the test substance were selected at 150, 300, and 600 mg/kg. The dose level of the positive substance was selected at 2 mg/kg. The dose volume was selected at 10 mL/kg for all groups, and the individual dose was calculated based on the bodyweight of animals just prior to dosing.

Measurement of tumor volume: The largest diameter (a) and the smallest diameter (b) of each tumor were measured using calipers twice a week during the observation period. The tumor volume (TV) was calculated twice a week according to the following formula: $TV (mm^3) = (a (mm) \times b^2 (mm^2))/2$. The volume of a tumor before administration to each animal was set to the value measured at the time of group assignment.

Tumor removal and measurement of body weight: After the observation period, animals were anesthetized by inhalation of isoflurane. After the tumor was extracted, the weight of the removed tumor was recorded. The tumor growth inhibition rate (IR) was calculated using the following formula: $IR (\%) = (1 - T/C) \times 100$, where T is a mean tumor weight in the test substance group, and positive substance group, and C is a mean tumor weight in the negative control group.

Histopathological test: The extracted tumors were fixed in 10% neutral buffered formalin solution (10% neutral buffered formalin). After sectioning the tumors to a certain thickness (about 3 mm), those were subjected to the general preparation procedure,

embedded in paraffin, cut into 4 to 5 μm size, and tissue sections were stained with Hematoxylin and Eosin (H&E) and TUNEL. IHC (Immunohistochemistry) slides, cut into 4 to 5 μm size, were produced and sent to the sponsor (Negative Control Group (G1), Test substance 2 (G3, Animal ID Nos.: 1301, 1302, 1303, 1307, 1310), Test substance 3 (G4, Animal ID Nos.: 1401, 1402, 1404, 1408, 1409)).

Determination of Hematoxylin & Eosin (H&E) staining results: Necrosis of tumors was assessed by grading ($\pm$, +, ++, +++, +++) the extent of necrosis in the whole section of the tumor. Necrosis was evaluated by morphological changes such as collapse or disappearance of the nucleus and eosinophilic change of cytoplasm. The extent of tumor necrosis was determined by the percentage of the following necrosis area.

Severity	Rate (%)
Minimal ($\pm$)	0 ~ 15
Slight (+)	15 ~ 45
Moderate (++)	45 ~ 70
Marked (+++)	70 ~ 85
Severe (++++)	85~

Table 3. Necrosis grading.

Determination of TUNEL staining results: After histological examination of the entire cross-section of the tumor for grading ($\pm$, +, ++, +++, +++) of apoptosis, the nucleated brown stained cells were read as benign cells, and the number of benign cells was counted. The apoptosis of the tumor was determined by the number of positive cells per histogram area (1 mm^2). The apoptosis of the tumor was determined by calculating the average number of positive cells and graded into the corresponding severity. The number of positive cells in which apoptosis occurred was determined by counting the number of positive cells per unit area (1 mm^2).

Severity	Apoptosis No.
Minimal ($\pm$)	5 ~ 10
Slight (+)	11 ~ 20
Moderate (++)	21 ~ 30
Marked (+++)	31 ~ 40
Severe (++++)	41 ~

Table 4. Apoptosis grading

Statistical Analysis: Statistical analysis was conducted using a statistical program (Version 9.3, SAS Institute Inc., U.S.A.) for the data, including body weights, tumor volume, tumor weight, and histopathological test. Bartlett's test was employed on the homogeneity of variance (significance level: 0.05). One-way analysis of variance (ANOVA) was employed on homogeneous data. Then if significant, Dunnett's t-test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed). Kruskal-Wallis test was employed on overridden homogeneous data. Then if significant, Steel's test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed).

Results

Change of tumor volume (Figures 1, 3, 4, 5, 6, and Table 5): In the negative control group (G1), the mean tumor volume ranged from 99 to 1576 mm³ before and 29 days after the administration of the control, with a tendency to increase over time (Figures 1, 3, and 4).

Group/ Dose (mg/kg)		Tumor volume (mm ³)								
		Time after administration (days)								
		1	5	8	12	15	19	22	26	29
G1 0	Mean	99	160	248	366	531	735	897	1235	1576
	S.D.	8	13	14	33	52	80	138	185	287
	N	10	10	10	10	10	10	10	10	10
G2 150	Mean	99	152	200	240	243	306	376	466	603
	S.D.	8	14	35	66	54	92	130	183	254
	N	10	10	10	10	10	10	10	10	10
				##	##	**	**	**	**	**
G3 300	Mean	99	146	172	182	212	254	310	390	460
	S.D.	8	16	14	24	54	90	131	177	228
	N	10	10	10	10	10	10	10	10	10
				##	##	**	**	**	**	**
G4 600	Mean	99	149	176	179	209	249	288	331	407
	S.D.	8	13	13	26	46	86	121	159	210
	N	10	10	10	10	10	10	10	10	10
				##	##	**	**	**	**	**
G5	Mean	99	152	171	176	199	250	314	385	481

2	S.D.	8	11	26	37	51	79	127	152	216
	N	10	10	10	10	10	10	10	10	10
				##	##	**	**	**	**	**

Table 5. Mean tumor volume during the observation period.

In Table 5, G1 refers to a negative control group. G2, G3, and G4 refer to OKN-007 treated groups. G5 refers to a cisplatin-treated group. S.D refers to a standard deviation. N refers to the number of animals. ## $p < 0.01$ refers to a significant difference from the negative control group (G1) by Steel's t-test. ** $p < 0.01$ refers to a significant difference from the negative control group (G1) by Dunnett's t-test.

In the 150 mg/kg test substance 1 (OKN-007) group (G2), there was a decrease in mean tumor volume, ranging from 99 to 603 mm³, which reaches statistical significance of difference ($p < 0.01$: 8 to 29 days after the administration) from the negative control group (G1) at a certain measurement point from all dose levels. See Figures 1 and 4.

In the 300 mg/kg test substance 2 (OKN-007) group (G3), there was a decrease in mean tumor volume, ranging from 99 to 460 mm³, which reaches statistical significance of difference ($p < 0.01$: 8 to 29 days after the administration) from the negative control group (G1) at a certain measurement point from all dose levels. See Figures 1 and 5.

In the 600 mg/kg test substance 3 (OKN-007) group (G4), there was a decrease in mean tumor volume, ranging from 99 to 407 mm³, which reaches statistical significance of difference ($p < 0.01$: 8 to 29 days after the administration) from the negative control group (G1) at a certain measurement point from all dose levels. See Figures 1 and 5.

In the 2 mg/kg positive control (Cisplatin) group (G5), there was a decrease in mean tumor volume, ranging from 99 to 481 mm³, which reaches statistical significance of difference ($p < 0.01$: 8 to 29 days after the administration) from the negative control group (G1) at a certain measurement point from all dose levels. See Figures 1 and 6.

Tumor weights and growth inhibition rate (Figure 2, 3, 4, 5, 6, and Table 6): The tumors were extirpated and weighted at day 29. In the negative control group (G1), the average tumor weight was 0.92 g (tumor growth inhibition rate (IR): 0.0%).

Group/ Dose (mg/kg)		Tumor weights (g)	IR (%)
G1	Mean	0.92	0.0
0	S.D.	0.34	
	N	10	

G2	Mean	0.47	48.9
150	S.D.	0.28	
	N	10	
		**	
G3	Mean	0.43	53.3
300	S.D.	0.27	
	N	10	
		**	
G4	Mean	0.38	58.7
600	S.D.	0.24	
	N	10	
		**	
G5	Mean	0.37	59.8
2	S.D.	0.27	
	N	10	
		**	

Table 6. Mean data of tumor weights and tumor growth inhibition rate.

In Table 6, G1 refers to a negative control group. G2, G3, and G4 refer to OKN-007 treated groups. G5 refers to a cisplatin-treated group. S.D refers to a standard deviation. IR refers to the following equation: (Tumor growth inhibition rate, %) = $(1 - T/C) \times 100$, where T is a mean tumor weight of the test and positive substance group, and C is a mean tumor weight of the negative control group. ** p<0.01 refers to a significant difference from the negative control group (G1) by Dunnett's t-test. See Figures 2.

In the 150 mg/kg test substance 1 (OKN-007) group (G2), the mean value of tumor weights was 0.47 g (tumor growth inhibition rate (IR): 48.9%). There was the statistical significance of the difference between the negative control and group 2. See Figures 2.

In the 300 mg/kg test substance 2 (OKN-007) group (G3), the mean value of tumor weights was 0.43 g (tumor growth inhibition rate (IR): 53.3%). There was the statistical significance of the difference between the negative control and group 3. See Figures 2.

In the 600 mg/kg test substance 3 (OKN-007) group (G4), the mean value of tumor weights was 0.38 g (tumor growth inhibition rate (IR): 58.7%). There was the statistical significance of the difference between the negative control and group 4. See Figures 2.

In the 2 mg/kg positive control (Cisplatin) group (G5), the mean value of tumor weights was 0.37 g (tumor growth inhibition rate (IR): 59.8%). There was the statistical significance of the difference between the negative control and group 5. See Figures 2.

Histopathological test (Table 7, Figures 7-11): The extracted fixed tumor was cut to a certain thickness (about 3 mm), then subjected to general tissue treatment, paraffin-embedded to produce blocks, and tissue sections of 4 to 5 μm in size were prepared. Then, Hematoxylin & Eosin (H&E) staining and TUNEL staining were performed.

Necrosis of extracted tumors was evaluated by H&E staining. As a result, the severity of tumor necrosis was mostly observed at the lowest severity in all treatment groups, which from the necrosis grading applies to minimal, slight, and moderate severity. The severity of necrosis between the test substance groups (G2, G3, and G4) and the positive control (Cisplatin) group (G5) does not significantly different compared to that of the negative control group (G1).

Apoptosis was confirmed by the TUNEL assay, and the apoptosis cells were counted accordingly. As a result, apoptosis increased in all administration groups compared to the negative control group (G1). Apoptosis was increased in all administration groups.

Group/ Dose (mg/kg)	N	Apoptosis						Necrosis				
		Counting										
		No.*	±	+	++	+++	++++	±	+	++	+++	++++
		(No./mm ²)										
G1 / 0	10	65.3±27.7	9	1	0	0	0	5	4	1	0	0
G2 / 150	10	79.6±20.8 ^{##}	9	1	0	0	0	5	3	2	0	0
G3 / 300	10	91.5±32.2 ^{##}	8	2	0	0	0	7	2	1	0	0
G4 / 600	10	149.9±59.5 ^{##}	3	5	2	0	0	6	2	2	0	0
G5 / 2	10	87.5±50.6	8	2	0	0	0	6	2	2	0	0

Table 7. Summary of Histopathological Findings.

In Table 7, G1 refers to a negative control group. G2, G3, and G4 refer to OKN-007 treated groups. G5 refers to a cisplatin-treated group. S.D refers to a standard deviation. N refers to the number of animals. ^{##} p<0.01 refers to a significant difference from the negative control group (G1) by Steel's t-test. * refers to group means $\pm$ S.D. $\pm$ refers to a minimal grade. + refers to a mild grade, ++ refers to a moderate grade, +++

refers to a marked grade, ++++ refers to a severe grade. Necrosis is determined by H&E Stain analyses. Apoptosis is determined by TUNEL assay.

In the negative control group (G1), the mean value of apoptosis counting was 65.3 ± 27.7 . See Figure 7 and Table 7.

5 In the 150 mg/kg test substance 1 (OKN-007) group (G2), the mean value of apoptosis counting was 79.6 ± 29.8 . There was a statistically significant difference ($p < 0.01$) compared to the negative control group (G1). See Figure 8 and Table 7.

10 In the 300 mg/kg test substance 2 (OKN-007) group (G3), the mean value of apoptosis counting was 91.5 ± 32.2 . There was a statistically significant difference ($p < 0.01$) compared to the negative control group (G1). See Figure 9 and Table 7.

In the 600 mg/kg test substance 3 (OKN-007) group (G4), the mean value of apoptosis counting was 149.9 ± 59.5 . There was a statistically significant difference ($p < 0.01$) compared to the negative control group (G1). See Figure 10 and Table 7.

15 In the 2 mg/kg positive control (Cisplatin) group (G5), the mean value of apoptosis counting was 87.5 ± 50.6 . There was no statistically significant difference compared to the negative control group (G1). See Figure 11 and Table 7.

20 As a result, mice that received 600 mg/kg test substance per oral gavage (G4) had the highest apoptosis counting among all groups, then 300 mg/kg test substance group (G3), 2 mg/kg positive control (Cisplatin) group (G5) and 150 mg/kg test substance group (G2) compared with the negative control group (G1).

Discussion

The purpose of this study was to evaluate *in vivo* anti-cancer efficacy of the test substance OKN-007 after its oral administration in nude mice carrying human A549 lung cancer xenografts implanted subcutaneously in the flank.

25 The human tumor xenograft system carried out in this study provides a useful model for experimental cancer therapy studies as nude mice are known for their weak immune rejection due to the deficiency of T-lymphocytes.

30 Tumor inhibition efficacy was evaluated by measuring the tumor volume and weight. When the values of tumor volume and weight were reduced compared to the negative control group and such results were considered statistically significant, the test substance was regarded as effective for anti-tumor therapy.

In tumor volume, the smallest to largest tumor volume was 600 mg/kg test substance group (G4), then 300 mg/kg test substance group (G3), 2 mg/kg positive control (Cisplatin) group (G5), and 150 mg/kg test substance group (G2) compared to the negative

control group (G1). The tumor volume is correlated with the tumor area. For example, similar to the data related to decreased tumor volume, the tumor area and/or growth of tumor area decreases after the OKN-007 treatment.

5 In tumor weight, 2 mg/kg positive control (Cisplatin) group (G5) showed the lowest. This suggests that the positive control has tumor growth inhibitory effect on tumor growth. The next lowest tumor weight was 600 mg/kg test substance group (G4), 300 mg/kg test substance group (G3), 150 mg/kg test substance group (G2), and the negative control group being the highest.

10 Regarding tumor growth inhibition rate, the highest to lowest were 2 mg/kg positive control (Cisplatin) group (G5) resulting 59.8% inhibition, then 600 mg/kg test substance group (G4) (58.7% inhibition), 300 mg/kg test substance group (G3) (53.5% inhibition) and 150 mg/kg test substance group (G2) (48.9% inhibition) when compared to the negative control (0.0% inhibition).

15 Moreover, the statistical analysis and the gravimetric measurement data of the extracted tumors from all study groups were considered statistically significant.

Apoptosis was evaluated with TUNEL assay, and the result of the assay was an increase in apoptosis in all administration groups compared to the negative control. 600 mg/kg test substance group (G4) was showing the highest level of apoptotic activity among all groups, then 300 mg/kg test substance group (G3), 2 mg/kg positive control (Cisplatin) group (G5), and 150 mg/kg test substance group (G2) compared to the negative control. All of the test groups except the positive control were considered statistically significant.

20 It was determined that the tumor growth inhibitory effect of the test substance was dose-dependent, and the test substance was considered to have a tumor growth inhibitory effect.

25 In conclusion, the dose-dependent inhibitory effect of the test substance (OKN-007) on tumor growth was observed in human lung cancer A549 xenografts in nude mice. A clinically relevant amount of OKN-007 can be used for human applications to induce the clinically relevant anti-cancer and/or anti-tumor effects. For example, OKN-007 at a concentration range from about 10 mg/kg body weight/day to about 500 mg/kg body weight/day can be used for systemic, intravenous, or local administration to a human subject. OKN-007 at a concentration range from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day can be used for oral or enteral administration to a human subject.

References

- [0100] Guanjai Dai et al., Myricanol Induces Apoptotic Cell Death and Anti-Tumor Activity in Non-Small Cell Lung Carcinoma in Vivo, International Journal of Molecular Sciences. 2015 Jan.; 16(2): 2717-2731.
- 5 [0101] Rhyu JJ et al., Dual effects of human adipose tissue-derived mesenchymal stem cells in human lung adenocarcinoma A549 xenografts and colorectal adenocarcinoma HT-29 xenografts in mice, Oncology Reports. 2015 Oct.; 34(4): 1733-1744.
- [0102] Towner, et al., OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth, Translational Oncology, 10 2019 Feb.; 12(2): 320–335.
- [0103] Towner, et al., Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitro OKN-007, Neuro Oncology 2013 Jan.; 15(3): 330-340

* * *

15 All patents, patent applications, publications, product descriptions, and protocols cited in this specification are hereby incorporated by reference in their entireties. In case of a conflict in terminology, the present disclosure controls.

While it will become apparent that the subject matter herein described is well calculated to achieve the benefits and advantages set forth above, the presently disclosed subject matter is not to be limited in scope by the specific embodiments described herein.

20 It will be appreciated that the disclosed subject matter is susceptible to modification, variation, and change without departing from the spirit thereof. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.

25 Various publications and nucleic acid and amino acid sequence accession numbers are cited herein, the contents and full sequences of which are hereby incorporated by reference herein in their entireties.

WHAT IS CLAIMED IS:

1. A method for treating a cancer or a tumor in a subject in need thereof, wherein the method comprises administering a therapeutically effective amount of 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount decreases a growth of the cancer or the tumor.
2. The method of claim 1, wherein the cancer is a non-small cell lung carcinoma.
3. The method of any one of claims 1-2, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof is from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day.
4. The method of any one of claims 1-3, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof is delivered to the subject via an intravenous injection or an intra-arterial injection.
5. The method of any one of claims 1-4, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof is delivered to the subject via an enteral administration or an oral administration.
6. The method of any one of claims 1-5, further comprising measuring a volume, an area, or a combination thereof of the cancer or the tumor.
7. The method of claim 6, wherein the cancer volume or the tumor volume decreases by at least about 50% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof.
8. The method of claim 6, wherein the growth of the cancer or the tumor decreases by at least about 40% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof.
9. The method of any one of claims 1-5, further comprising counting apoptotic cancer cells or apoptotic tumor cells.
10. The method of claim 9, wherein a number of the apoptotic cancer cells or the apoptotic tumor cells increases by at least about 15% after administering the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof.

11. The method of any one of claims 1-10, the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof is delivered to the subject at least once a week.
12. The method of any one of claims 1-11, further comprising administering a therapeutically effective amount of an anti-cancer agent or anti-tumor agent to the subject.
13. The method of claim 12, wherein the anti-cancer agent or anti-tumor agent is selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a cytokine, an anti-angiogenic agent, a tyrosine kinase inhibitor (TKI), an apoptosis-inducing agent, an anti-cancer antibody, and combinations thereof.
14. The method of any one of claims 1-13, further comprising administering an additional therapy, wherein the additional therapy is selected from the group consisting of an anti-tumor therapy, an anti-cancer therapy, a chemotherapy, a targeted therapy, an immunotherapy, a radiation therapy, a radiofrequency ablation therapy, surgery, a therapy using a tumor treating fields (TTFields) device, or combinations thereof.
15. A pharmaceutical composition for treating a cancer or a tumor in a subject comprising a therapeutically effective amount of 2,4-disulfonyl α -phenyl tert-butyl nitron (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount is present in an amount to decrease a growth of the cancer or the tumor.
16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is in a form of a tablet, a pill, a capsule, a gel, a liquid, a syrup, a slurry, or a suspension for an oral administration or an enteral administration.
17. The pharmaceutical composition of claim 16, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof is from about 5 mg/kg body weight/day to about 1,000 mg/kg body weight/day.
18. The pharmaceutical composition of any one of claims 15-17, wherein the composition comprises at least one coating layer, wherein the at least one coating layer encapsulates the 2,4-ds-PBN or pharmaceutically acceptable salts thereof and solubilizes at a predetermined range of pH.
19. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is in a form of a solution or a liquid for an intravenous injection or an intra-arterial injection.

20. The pharmaceutical composition of claim 19, wherein the therapeutically effective amount of the 2,4-ds-PBN or pharmaceutically acceptable salts thereof is from about 10 mg/kg body weight/day to about 500 mg/kg body weight/day.
21. The pharmaceutical composition of any one of claims 15-20, wherein the cancer is a non-small cell lung carcinoma.

1/11




Figure 1

2/11




Figure 2

3/11






Figure 3

4/11




G1: Negative control
(0 mg/kg)




G2: OKN-007
(150 mg/kg)

Figure 4

5/11




G3: OKN-007
(300 mg/kg)



G4: OKN-007
(600 mg/kg)

Figure 5


6/11




G5: Cisplatin
(2 mg/kg)

Figure 6

7/11




<H & E Stain>




<TUNEL assay>
G1 (Animal ID: 1107)
Negative control (0 mg/kg)

Figure 7

8/11




<H & E Stain>




<TUNEL assay>
G2 (Animal ID: 1208)
OKN-007 (150 mg/kg)

Figure 8

9/11




<H & E Stain>




<TUNEL assay>
G3 (Animal ID: 1306)
OKN-007 (300 mg/kg)

Figure 9

10/11




<H & E Stain>




<TUNEL assay>
G4 (Animal ID: 1404)
OKN-007 (600 mg/kg)

Figure 10

11/11



<H & E Stain>



<TUNEL assay>
G5 (Animal ID: 1509)
Cisplatin (2 mg/kg)

Figure 11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US21/19457

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 31/15; A61K 9/48; A61K 31/185; A61P 27/16; A61P 35/00; A61P 35/02 (2020.01)

CPC - A61K 31/15; A61K 9/48; A61K 31/185; A61P 27/16; A61P 35/00; A61P 35/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2017/0027891 A1 (OKLAHOMA MEDICAL RESEARCH FOUNDATION) 2 February 2017; abstract; figure 3; paragraphs [0005], [0013], [0015], [0028], [0056], [0068], [0109], [0112], [0115]; claims 35, 37	1, 3/1, 15-17, 19-20 --- 3/1-2, 18
X --- Y	US 2015/0258046 A1 (TOSK, INC.) 17 September 2015; abstract; paragraphs [0172], [0194], [0225], [0228]-[0229], [0241], [0243], [0257]	1-2 --- 3/1-2
Y	US 2018/0200192 A1 (OTOLOGIC PHARMACEUTICS, INC.) 19 July 2018; abstract; paragraphs [0007], [0011], [0028], [0034], [0054]; claim 21	18



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 April 2021 (15.04.2021)

Date of mailing of the international search report

MAY 07 2021

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US21/19457

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-14, 21
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.